Please ensure Javascript is enabled for purposes of website accessibility

Here's What You'll Want to Know About Incyte's Impressive Q2 Results

By Keith Speights - Jul 30, 2019 at 4:00PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The biotech beat Wall Street revenue and earnings estimates in Q2. And it could have more good news on the way.

Incyte (INCY -0.81%) has been on a roll so far in 2019. The biotech's shares have soared. The company reported strong first-quarter results in April. 

Incyte updated investors of its performance in the second quarter on Tuesday, announcing its second-quarter results before the market opened. The company appears to be keeping its momentum going. Here's what you need to know about the biotech's Q2 results. 

Scientist holding a beaker

Image source: Getty Images.

By the numbers

Incyte announced Q2 revenue of $529.9 million, a 1.6% increase from the $521.5 million reported in the same quarter of the previous year. The company's reported revenue was higher than the average analysts' revenue estimate of $497.8 million.

How did Incyte's bottom line look in Q2? The company reported net income of $105.3 million under generally accepted accounting principles (GAAP), compared to $52.4 million in the same period in 2018. 

Incyte also announced second-quarter adjusted non-GAAP earnings of $162 million, or $0.75 per diluted share. This marked a 19% increase from adjusted earnings of $136 million, or $0.63 per diluted share, reported in the same quarter of 2018. It also trounced the consensus analysts' estimate of Q2 adjusted earnings of $0.48 per share.

Behind the numbers

Incyte's solid results stemmed primarily from continued success for its flagship drug, Jakafi. Net revenue for Jakafi jumped 18.5% year over year to $410 million. The biotech also receives product royalties from Novartis, which markets the drug under the brand name Jakavi outside the U.S. These royalties totaled $57 million in the second quarter, up from $47 million in the prior-year period.

The company's other two approved drugs also contributed to Incyte's growth in the second quarter. Net product revenue from Iclusig jumped 20% year over year to $24 million. Product royalties for Olumiant, which Incyte licensed to Eli Lilly, soared 111% to $19 million.

Operating costs and expenses were 1.6% lower in Q2 than in the same period of 2018. Operating income rose 19% in the second quarter to $99 million from the previous year's quarter of $83 million.

One key development for Incyte during the second quarter was the FDA approval in May of Jakafi in treating steriod-refractory graft-versus-host disease (GVHD). This marked the third indication for which the drug has won approval in the U.S.

Looking ahead

Incyte now anticipates Jakafi revenue between $1.61 billion and 1.65 billion in for the full year. This reflects a narrowing from its previous guidance of $1.58 billion to $1.65 billion. The company also continues to expect that sales for Iclusig in 2019 will be between $90 million and $100 million.

Investors can also look forward to key pipeline developments for Incyte. CEO Herve Hoppenot said that the company is "on track to file a New Drug Application (NDA) seeking approval of pemigatinib in cholangiocarcinoma [also known as bile duct cancer] in the second half [of 2019], and we look forward to announcing the results of multiple pivotal trials of ruxolitinib [the active ingredient in Jakafi] and itacitinib in GVHD by year-end."

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Incyte Corporation Stock Quote
Incyte Corporation
$74.90 (-0.81%) $0.61
Eli Lilly and Company Stock Quote
Eli Lilly and Company
$291.63 (0.28%) $0.81
Novartis AG Stock Quote
Novartis AG
$85.82 (0.52%) $0.44

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/16/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.